Denali Therapeutics Inc. (DNLI) Performance and Fundamentals Dashboard tells a completely different story

Denali Therapeutics Inc. (NASDAQ: DNLI) stock jumped 1.95% on Tuesday to $30.28 against a previous-day closing price of $29.70. With 0.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.69 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $30.64 whereas the lowest price it dropped to was $29.05. The 52-week range on DNLI shows that it touched its highest point at $39.43 and its lowest point at $20.24 during that stretch. It currently has a 1-year price target of $62.86. Beta for the stock currently stands at 1.36.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNLI was up-trending over the past week, with a rise of 0.60%, but this was up by 7.19% over a month. Three-month performance surged to 6.92% while six-month performance fell -14.32%. The stock lost -6.43% in the past year, while it has gained 8.88% so far this year. A look at the trailing 12-month EPS for DNLI yields -2.46 with Next year EPS estimates of -2.99. For the next quarter, that number is -0.79. This implies an EPS growth rate of -478.80% for this year and -15.90% for next year.

Float and Shares Shorts:

At present, 123.47 million DNLI shares are outstanding with a float of 115.72 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.29 million, which was 5.89% higher than short shares on Sep 14, 2022. In addition to Dr. Ryan J. Watts Ph.D. as the firm’s Co-Founder, Pres, CEO & Director, Dr. Alexander O. Schuth M.D. serves as its Co-Founder, CFO, COO & Sec.


Institutional Ownership:

Through their ownership of 71.33% of DNLI’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.74% of DNLI, in contrast to 40.16% held by mutual funds. Shares owned by individuals account for 23.59%. As the largest shareholder in DNLI with 10.84% of the stake, Baillie Gifford & Co. holds 14,715,051 shares worth 14,715,051. A second-largest stockholder of DNLI, The Vanguard Group, Inc., holds 8,146,533 shares, controlling over 6.00% of the firm’s shares. Crestline Management LP is the third largest shareholder in DNLI, holding 7,160,732 shares or 5.27% stake. With a 4.81% stake in DNLI, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 6,532,566 shares are owned by the mutual fund manager. The Vanguard US Growth Fund, which owns about 2.61% of DNLI stock, is the second-largest Mutual Fund holder. It holds 3,544,134 shares valued at 98.56 million. Vanguard Total Stock Market Index holds 2.31% of the stake in DNLI, owning 3,139,302 shares worth 87.3 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNLI since 17 analysts follow the stock currently. There are 15 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNLI analysts setting a high price target of $105.00 and a low target of $36.00, the average target price over the next 12 months is $64.33. Based on these targets, DNLI could surge 246.76% to reach the target high and rise by 18.89% to reach the target low. Reaching the average price target will result in a growth of 112.45% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DNLI will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$1.47 being high and -$2.90 being low. For DNLI, this leads to a yearly average estimate of -$2.55. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Denali Therapeutics Inc. surprised analysts by -$0.04 when it reported -$0.84 EPS against a consensus estimate of -$0.80. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.41 and the low estimate is -$0.98. The average estimate for the next quarter is thus -$0.79.

Summary of Insider Activity:

Insiders traded DNLI stock several times over the past three months with 3 Buys and 13 Sells. In these transactions, 164,480 shares were bought while 69,718 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 417,486 while 254,986 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *